SciVision Biotech Inc. (TPE:1786)
Taiwan
· Delayed Price · Currency is TWD 68.20
+2.20 (3.33%)
Mar 10, 2026, 12:45 PM CST
SciVision Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 162.34 | 242.25 | 177.9 | 141.72 | 101.72 | Upgrade
|
| Depreciation & Amortization | 80.43 | 65.14 | 63.05 | 62.02 | 52.98 | Upgrade
|
| Other Amortization | - | 0.08 | 0.08 | 0.04 | 0.04 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.01 | -0.19 | -0.54 | -30.55 | -0.13 | Upgrade
|
| Loss (Gain) From Sale of Investments | 2.13 | -6.45 | -2.9 | 1.98 | 0.13 | Upgrade
|
| Other Operating Activities | -4.07 | 25.99 | 7.43 | 18.12 | -2.23 | Upgrade
|
| Change in Accounts Receivable | -75.5 | -73.55 | -4.85 | -7.77 | -10.47 | Upgrade
|
| Change in Inventory | -13.74 | 14.45 | 8.62 | -13 | -37.03 | Upgrade
|
| Change in Accounts Payable | 3.13 | 6.52 | -3.21 | 6.77 | -11.33 | Upgrade
|
| Change in Unearned Revenue | -1.13 | -4.34 | 6.32 | -1.01 | -5.6 | Upgrade
|
| Change in Other Net Operating Assets | -29.6 | -0.04 | 20.11 | 3.68 | 10.41 | Upgrade
|
| Operating Cash Flow | 123.99 | 269.87 | 272.01 | 181.99 | 98.51 | Upgrade
|
| Operating Cash Flow Growth | -54.06% | -0.79% | 49.47% | 84.75% | -22.11% | Upgrade
|
| Capital Expenditures | -101.53 | -34.76 | -14.73 | -14.96 | -25.78 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.19 | 1.26 | 56.48 | 21.13 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.23 | -0.12 | -0.11 | - | - | Upgrade
|
| Investment in Securities | -39.79 | 134 | -201.79 | -48.49 | -20.89 | Upgrade
|
| Other Investing Activities | -1.19 | -1.79 | 2.01 | 52.79 | -51.47 | Upgrade
|
| Investing Cash Flow | -142.74 | 97.52 | -213.37 | 45.81 | -77.01 | Upgrade
|
| Short-Term Debt Issued | 2 | - | - | - | 10 | Upgrade
|
| Long-Term Debt Issued | 400 | - | - | 700 | 1,200 | Upgrade
|
| Total Debt Issued | 402 | - | - | 700 | 1,210 | Upgrade
|
| Short-Term Debt Repaid | -1.49 | - | - | - | -10 | Upgrade
|
| Long-Term Debt Repaid | -8.1 | -3.35 | -1.23 | -905.89 | -901.39 | Upgrade
|
| Total Debt Repaid | -9.6 | -3.35 | -1.23 | -905.89 | -911.39 | Upgrade
|
| Net Debt Issued (Repaid) | 392.4 | -3.35 | -1.23 | -205.89 | 298.61 | Upgrade
|
| Common Dividends Paid | -233.87 | -169.33 | -133.3 | -93.83 | -58.56 | Upgrade
|
| Other Financing Activities | - | 0.16 | - | 0.01 | - | Upgrade
|
| Financing Cash Flow | 158.53 | -172.52 | -134.53 | -299.71 | 240.06 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0 | 0.05 | -0.03 | 0.01 | -0.01 | Upgrade
|
| Net Cash Flow | 139.79 | 194.92 | -75.92 | -71.9 | 261.55 | Upgrade
|
| Free Cash Flow | 22.46 | 235.11 | 257.28 | 167.03 | 72.73 | Upgrade
|
| Free Cash Flow Growth | -90.45% | -8.62% | 54.04% | 129.64% | 21.97% | Upgrade
|
| Free Cash Flow Margin | 2.53% | 26.62% | 36.08% | 29.97% | 14.39% | Upgrade
|
| Free Cash Flow Per Share | 0.30 | 3.16 | 3.37 | 2.24 | 1.02 | Upgrade
|
| Cash Interest Paid | 0.03 | 0.99 | 0.42 | 2.99 | 1.12 | Upgrade
|
| Cash Income Tax Paid | 38.03 | 28.6 | 30.97 | 11.51 | 23.53 | Upgrade
|
| Levered Free Cash Flow | 45.44 | 134.06 | 189.21 | 99.15 | 9.36 | Upgrade
|
| Unlevered Free Cash Flow | 50.39 | 137.61 | 194.35 | 103.18 | 14.4 | Upgrade
|
| Change in Working Capital | -116.84 | -56.96 | 26.99 | -11.33 | -54.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.